StudyFinder

RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER

Recruiting
I'm interested

This study is NOT accepting healthy volunteers

Anatomic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8

Lauren Aase - lauren.aase@parknicollet.com
Nicole Hartung
0123456789
NCT03723928
See this study on ClinicalTrials.gov

Back